Aclaris Therapeutics (ACRS) to Release Quarterly Earnings on Tuesday

Aclaris Therapeutics (NASDAQ:ACRS) will release its earnings data after the market closes on Tuesday, November 6th. Analysts expect Aclaris Therapeutics to post earnings of ($1.25) per share for the quarter.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%. The firm had revenue of $3.68 million for the quarter, compared to the consensus estimate of $2.76 million. On average, analysts expect Aclaris Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of NASDAQ ACRS opened at $12.22 on Friday. Aclaris Therapeutics has a fifty-two week low of $11.00 and a fifty-two week high of $26.25.

ACRS has been the topic of several research analyst reports. Zacks Investment Research raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 29th. JMP Securities dropped their price objective on Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating on the stock in a research note on Tuesday, October 16th. BidaskClub raised Aclaris Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 13th. Finally, Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Aclaris Therapeutics currently has a consensus rating of “Buy” and an average price target of $41.60.

In other news, Director Stephen A. Tullman acquired 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were bought at an average price of $15.97 per share, with a total value of $99,812.50. Following the completion of the purchase, the director now directly owns 163,757 shares in the company, valued at $2,615,199.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stephen A. Tullman bought 6,600 shares of the company’s stock in a transaction on Thursday, August 23rd. The shares were bought at an average cost of $15.00 per share, for a total transaction of $99,000.00. Following the transaction, the director now directly owns 170,357 shares in the company, valued at approximately $2,555,355. The disclosure for this purchase can be found here. In the last three months, insiders purchased 392,043 shares of company stock worth $4,298,212. 17.00% of the stock is owned by insiders.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Read More: How a Put Option Works

Earnings History for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply